Clinical studies of adoptive immunochemotherapy combined with anti-cancer agents in the treatment of malignant bone tumor

1994 Fiscal Year Final Research Report Summary

• Project/Area Number: 05671210
• Research Category: Grant-in-Aid for General Scientific Research (C)
• Allocation Type: Single-year Grants
• Research Field: Orthopaedic surgery
• Research Institution: Gifu University
• Principal Investigator: TAKTEUCHI Shoji Gifu University, College of Medical Sciences, Professor, 医療技術短期大学部, 教授 (50021473)
• Co-Investigator(Kenkyū-buntansha): SEISHIMA Mitsuru Gifu University, School of Medicine, Assistant Professor, 医学部, 講師 (10171315) ; NOMA Akio Gifu University, School of Medicine, Professor, 医学部, 教授 (30208384)
• Project Period (FY): 1993 – 1994
• Keywords: malignant bone tumor / anti-cancer agent / BRM / immunochemotherapy / intra-arterial infusion chemotherapy

Research Abstract

In order to evaluate the biological response after intraarterial and intravenous administration anti-cancer agents, we studied the changes of cytokine levels in serum.
Four types of cytokines (IL-1beta, IL-2, IL-6, TNF-alpha) were measured by ELISA method. A significant increase of IL-6 and TNF-alpha production was observed after intravenous infusion of anti-cancer agents.
After intraarterial infusion of agents there was a slight increase in the production of these cytokines.
On the other hand, there were no changes in the IL-1beta and IL-2 levels after infusion of the agents.
IL-6 and TNF-alpha increased almost at the same time that the numbers of WBC decreased after infusion.
And this phenomenon was clear in the patients who had a good performance status.
Further studies should be done to confirm the efficacy of the adoptive immunochemotherapy combined with anti-cancer agents for malignat bone tumor.